This is the authors' abstract. We don't add key points for this paper.
Choice of second-line treatment of patients with ITP remains uncertain in the absence of randomized controlled trials comparing leading second-line agents: thrombopoietic agents (TPO) and rituximab with/without dexamethasone (Dex-Ritux) and splenectomy (SPL) (which may be underutilized). The ASH Guidelines and the Consensus document could not clarify which agent was superior given the absence of data. This study compares 3 leading second-line agents of ITP, considering each as a strategy with rapid change to another treatment option if the first option is ineffective or toxic. Markov states were assessed monthly and patients divided into “curable”, responsive but incurable, or unresponsive. TPO use was limited to 1 year if “cure” was not achieved unless the patient was unresponsive to SPL and Dex-Ritux but remained responsive to TPO. Leading toxicities were incorporated: sepsis and thrombosis for splenectomy and thrombosis for TPO. The results demonstrated relatively modest differences among the treatments. Starting with Dex-Ritux had the longest life expectancy whereas splenectomy was the least expensive but had the shortest life expectancy. TPO was the most costly. Differences were smallest in 60 year-old men and women; but even in the base-case 40 year-old woman, the maximum difference in life expectancy was less than 0.7 years and the added cost of the life expectancy was less than $30,000 per year of life. Incremental cost-effectiveness ratios were helpful in comparing different options. This Markov model suggested that any of TPO, Dex-Ritux, or SPL were reasonable initial second-line options when used as needed and based on shared-decision making.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Skopec et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: